Sugi Predict

Sugi Predict / Compounds / SCHEMBL384924

SCHEMBL384924

SCHEMBL384924

C[C@H](NC1CCNCC1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 4/20 0.47
▸ POLB P06746 1/20 0.42
▸ GABRP O00591 1/20 0.40
▸ GABRD O14764 1/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ GABRB1 P18505 1/20 0.40
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40
▸ GABRA5 P31644 1/20 0.40
▸ GABRA3 P34903 1/20 0.40
▸ GABRA2 P47869 1/20 0.40
▸ GABRB2 P47870 1/20 0.40
▸ GABRA4 P48169 1/20 0.40
▸ GABRE P78334 1/20 0.40
▸ PMP22 Q01453 1/20 0.40
▸ GABRA6 Q16445 1/20 0.40
▸ GABRG1 Q8N1C3 1/20 0.40
▸ GABRG3 Q99928 1/20 0.40
▸ GABRQ Q9UN88 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL384923 1.00 EPHX1 (0.47) EPHX1POLBGABRPGABRDGABRA1
SCHEMBL6371199 1.00 EPHX1 (0.47) EPHX1POLBGABRPGABRDGABRA1
SCHEMBL31109672 0.89 KCNH2 (0.41) EPHX1POLBGABRPGABRDGABRA1
SCHEMBL825689 0.89 KCNH2 (0.41) EPHX1POLBGABRPGABRDGABRA1
SCHEMBL825809 0.89 KCNH2 (0.41) EPHX1POLBGABRPGABRDGABRA1
SCHEMBL154765 0.85 — —
SCHEMBL19138062 0.85 — —
SCHEMBL154766 0.85 — —
SCHEMBL1802725 0.82 EPHX1 (0.45) EPHX1POLBGABRPGABRDGABRA1
SCHEMBL1802729 0.82 EPHX1 (0.45) EPHX1POLBGABRPGABRDGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025109003-A1 P-CADHERIN LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-05-30 — — WO claimed
US-9796766-B2 Potent and selective inhibitors of NAV1.3 and NAV1.7 AMGEN INC. (US) 2017-10-24 — — US claimed
US-20160304570-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 AMGEN INC. (US) 2016-10-20 — — US claimed
US-9340590-B2 Potent and selective inhibitors of NaV1.3 and NaV1.7 AMGEN INC. (US) 2016-05-17 — — US claimed
US-20140073577-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 AMGEN INC. (US) 2014-03-13 — — US claimed
EP-2686340-A2 POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 Amgen Inc. (US) 2014-01-22 — — EP claimed
WO-2012125973-A2 POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 AMGEN INC. (US) 2012-09-20 — — WO claimed
EP-1991572-A2 PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN SYNTONIX PHARMACEUTICALS, INC. (US) 2008-11-19 — — EP claimed
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn BIOGEN HEMOPHILIA INC. 2007-11-01 — — US claimed
WO-2007098420-A2 PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN SYNTONIX PHARMACEUTICALS, INC. (US) 2007-08-30 — — WO claimed
US-20050119190-A1 Inhibitors of the blood-clotting factor xa, production thereof and use of the same CURACYTE AG (DE) 2005-06-02 — — US claimed
EP-1483285-A1 INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME Curacyte AG (DE) 2004-12-08 — — EP claimed
WO-2003076457-A1 INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME CURACYTE AG (DE) 2003-09-18 — — WO claimed
US-20250313835-A1 MICELLAR NANOPARTICLES AND USES THEREOF BIORCHESTRA CO., LTD. (KR) 2025-10-09 — — US disclosed
US-20250270255-A1 CASPASE-2 INHIBITOR COMPOUNDS KINTSUGI THERAPEUTICS S L (ES) 2025-08-28 — — US disclosed
EP-4603589-A2 MICELLAR NANOPARTICLES AND USES THEREOF Biorchestra Co., Ltd. (KR) 2025-08-20 — — EP disclosed
EP-0802916-A1 LOW MOLECULAR WEIGHT BICYCLIC THROMBIN INHIBITORS BIOCHEM PHARMA INC (CA) 1997-10-29 — — EP disclosed
WO-1996040743-A2 INHIBITORS OF FACTOR Xa COR THERAPEUTICS, INC. (US) 1996-12-19 — — WO disclosed
WO-1996037497-A1 LOW MOLECULAR WEIGHT BICYCLIC-UREA TYPE THROMBIN INHIBITORS BIOCHEM PHARMA INC. (CA) 1996-11-28 — — WO disclosed
WO-1996019483-A1 LOW MOLECULAR WEIGHT BICYCLIC THROMBIN INHIBITORS BIOCHEM PHARMA INC. (CA) 1996-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140073577-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 SCN7A, SCN3A, SCN9A EPHX1 4052/4885POLB 2041/4885GABRP 505/4885
US-20250270255-A1 CASPASE-2 INHIBITOR COMPOUNDS CASP2, CASP1, CASP3 EPHX1 2741/4885POLB 2871/4885GABRP 4033/4885
US-20050119190-A1 Inhibitors of the blood-clotting factor xa, production thereof and use of the same SERPINC1, TFPI, F11 EPHX1 205/4885POLB 4086/4885GABRP 1756/4885
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn FCGRT, FCGR3B, FCGR1A EPHX1 3281/4885POLB 4277/4885GABRP 465/4885
US-20250313835-A1 MICELLAR NANOPARTICLES AND USES THEREOF HNRNPLL, UACA, POLRMT EPHX1 3687/4885POLB 661/4885GABRP 1998/4885
US-20160304570-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 SCN7A, SCN3A, SCN9A EPHX1 4052/4885POLB 2041/4885GABRP 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.